Welcome to visitJiangsu High-wit Medical Ltd.Enterprise official website
service@jshaizhi.cn
13357821869
中文
Home
About
Company Profile
Honors
Plant Equipment
Partner
R&D Team
Intellectual Property
Blog
News Information
Industry News
Product R&D
Haibei Yan
Xieyanji
OEM/CDMO
OEM Service
CDMO Service
Contact
Industry Trends
Haizhi Biotech collaborates with Yunhe Pharmaceutical to promote the inheritance and innovation of traditional Chinese medicine.
The two founders of Jiangsu Haizhi Biotechnology were invited to visit Yunnan Yunhe Pharmaceutical Co., Ltd., where they received a warm welcome from Chairman Hu Songmou and his team members. Both parties have preliminarily reached a cooperation intention to focus on promoting the development and application of the national medicine dragon's blood resin resources.
10
2020
/
09
China Pharmaceutical University visited Jiangsu Haizhi Biotechnology to supervise research and development production and deepen school-enterprise cooperation.
On August 26, 2020, Professor Liu Jianping and Professor Sun Jianguo from China Pharmaceutical University, along with Director Zhu Xuanxuan from Jiangsu Provincial Hospital of Traditional Chinese Medicine, visited Jiangsu Haizhi Biopharmaceutical Co., Ltd. to supervise research and development production work. Both parties had in-depth discussions on the current cooperation project "Research and Development of a Series of Functional Wet Dressings." To continuously deepen the cooperation between the university and the enterprise and to serve the Healthy China strategy, Haizhi Biopharmaceutical has established a deep collaboration with China Pharmaceutical University since November 2017. They jointly develop product formulas, optimize production processes, tackle technical challenges, and closely connect cutting-edge scientific research achievements with market demands, achieving a win-win situation of resource sharing and complementary advantages.
04
Chief Scientist Liu Jianping
PhD in Pharmacy, doctoral supervisor at China Pharmaceutical University, chief scientist and technical leader of the key technology team for transdermal delivery and skin health products.
26
05
Chief Technology Officer Yang Zheng
China Pharmaceutical University, Master's Degree Over 20 years of experience in drug and medical device research and registration, Holds 4 authorized invention patents, 7 utility model patents, Published 6 academic papers.
General Manager Xu Liyou
China Pharmaceutical University, Master's degree EMBA from Asia Business School in Hong Kong, holding 21 invention and utility model patents, Founded Jiangsu Haizhi Biopharmaceutical Co., Ltd. in 2015.
A large number of drugs have been removed from the provincial medical insurance catalog! 68 varieties have entered a transition period.
The new "National Medical Insurance Drug List" has been in effect for two months, and some provinces have already started to make cuts to the originally added provincial drugs, temporarily retaining a portion while deleting others or listing them as self-paid.
21
Scientists decipher key factors in chronic hepatitis B virus infection, taking a step closer to a cure.
On the 10th, the journal Nature Microbiology published an online research paper regarding the hepatitis B virus (HBV). Scientists from Princeton University identified a group of proteins that decipher a key issue in the virus's life cycle, providing new directions for the treatment of chronic HBV infections.
The country's first peripheral drug-eluting stent has been approved for market launch.
On April 9, the National Medical Products Administration announced the approval of the registration of the priority product "Drug-Eluting Peripheral Vascular Stent" produced by Cook Ireland Limited.